Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
96 Results for "
LRRK2
" in MedChemExpress (MCE) Product Catalog:
Products (96)
96 Results for "LRRK2" in MCE Product Catalog:
Research Areas:
JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 promotes ubiquitination and degradation of LRRK2. JH-XII-03-02 can be used for the research of Parkinson's disease .
Cat. No.: HY-P5979
CAS No.: 1071466-49-3
Target:
Research Areas:
Cat. No.: HY-16936
CAS No.: 1700693-08-8
Target:
Research Areas:
JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .
Target:
Research Areas:
EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50: < 0.2 nM). EB-42486 can be used in the research of Parkinson's disease [2].
Cat. No.: HY-178796
CAS No.: 2839664-99-0
Research Areas:
PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC50 of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation .
Cat. No.: HY-178797
CAS No.: 3080678-98-1
Research Areas:
PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC50 of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation .
Cat. No.: HY-W663938
CAS No.: 400882-07-7
Research Areas:
Cyflumetofen is a non-systemic acylacetonitrile Acaricide. Cyflumetofen interferes with the Wnt/β-catenin signaling pathway, induces Apoptosis, and reduces the level of tight junction proteins. Cyflumetofen upregulates the expression of Pink1, Parkin and Lrrk2 genes associated with the pathogenesis of Parkinson's disease in zebrafish larvae. Cyflumetofen induces developmental toxicity and oxidative stress in zebrafish larvae, damages neurons, reduces motor activity, alters brain tissue structure, and disrupts blood-brain barrier structure. Cyflumetofen exhibits acaricidal activity against spider mites. Cyflumetofen can be used in studies related to Parkinson's disease and infestations by spider mites (Tetranychus urticae, Tetranychus kanzawai, Panonychus citri) [2].
Cat. No.: HY-153058
CAS No.: 2770269-44-6
Research Areas:
LRRK2-IN-8 is a LRRK2 inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC50s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC50s of 10-100 nM .
Target:
Research Areas:
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .
Cat. No.: HY-134562
CAS No.: 1622291-81-9
Target:
Research Areas:
PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .
Cat. No.: HY-W002458
CAS No.: 2075-46-9
Research Areas:
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .
Cat. No.: HY-174420
Target:
Research Areas:
RN277 is a selective LRRK2 inhibitor with an IC50 of 135 nM against LRRK2 RCKW kinase. RN277 inhibits LRRK2-mediated phosphorylation of Rab8a. RN277 rescues the motor activity of kinesin inhibited by LRRK2 RCKW in vitro, and its mechanism of action may involve preventing LRRK2 from forming filamentous structures on microtubules. RN277 can be used in studies related to Parkinson's disease .
Cat. No.: HY-174427
CAS No.: 3091508-57-2
Target:
Research Areas:
RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM). RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.
Cat. No.: HY-B0792A
CAS No.: 1784253-05-9
Target:
Research Areas:
CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC50 of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .
Cat. No.: HY-RS07833
Target:
Research Areas:
LRRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for LRRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS07834
Target:
Research Areas:
Lrrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS07835
Target:
Research Areas:
Lrrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-158365
CAS No.: 2942328-06-3
Target:
Research Areas:
LRRK2-IN-14 (Compound 8) is an orally active LRRK2 inhibitor. LRRK2-IN-14 has an IC50 of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC50=22 μM). LRRK2-IN-14 has blood-brain barrier permeability .
Cat. No.: HY-161570
CAS No.: 3032733-05-1
Target:
Research Areas:
LRRK2-IN-12 (compound 1) inhibits the activity of LRRK2 G20195 (IC50=0.45 nM), LRRK2 WT (IC50=1.1 nM) and LRRK2 WT ADP-Glo (IC50=0.46 nM). LRRK2-IN-12 can be used for Alzheimer's Disease research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
